| Monday June 13 |
| 09:00-10:00 |
Registration and coffee |
| |
|
| |
Oral session I |
Free communications I |
chair: Lewis Sheiner |
| 10:00-10:15 |
N. Baber |
Introduction |
| 10:15-10:30 |
C. Peck, T. Ludden |
Pitfalls in retrospective analysis in search of concentration-effect relationships |
| 10:30-10:45 |
M.O. Karlsson, S.L. Beal, L.B. Sheiner |
Three new residual error models for population PK/PD analyses |
| 10:45-11:00 |
J.R. Wade, S.L. Beal, N.C. Sambol |
Interaction between structural, statistical and covariate models in population pharmacokinetic analysis |
| 11:00-11:15 |
J.W. Mandema, D. Verotta, L.B. Sheiner |
Diagnostics for nonlinear mixed effects models |
| 11:15-11:30 |
Coffee break |
| |
|
| |
Oral session II |
Free communications II |
chair: Lewis Sheiner |
| 11:30-11:45 |
Y. Merle, F. Mentré |
Comparison of Bayesian optimal designs with respect to variations of the population characteristics for a pharmacokinetic and a pharmacodynamic model |
| 11:45-12:00 |
C. Efthymiopoulos, V. Cosson, A. Bye |
The use of NONMEM in the interspecies allometric scaling |
| 12:00-12:15 |
A.V. Boddy, M. Cole, P. Bin, A.D.J. Pearson, D.R. Newell |
A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics |
| 12:15-12:30 |
E. Chatelut, V. Brunner, C. Chevreau, A. Pujol, H. Roche, V. Paschel, G. Houin, R. Bugat, P. Canal |
Carboplatin population pharmacokinetics |
| 12:30-14:00 |
Lunch |
| |
|
| |
Oral session III |
Population approach in drug development : present state |
chair: Alison Thomson |
| 14:00-14:20 |
A. Bye |
Issues and suggested solutions in drug development (Logistics/Models/Regulatory) |
| 14:20-14:40 |
R. Bruno, N. Vivier, J.C. Vergniol, G. Montay, L.B. Sheiner |
A validation for a population pharmacokinetic model for docetaxel |
| 14:40-15:15 |
A. Grieve |
Combining studies: opportunities and pitfalls |
| 15:15-15:45 |
Tea break |
| |
|
| |
Oral session IV |
Population approach in drug development : future |
chair: Willi Weber |
| 15:45-16:05 |
J.-L Steimer, M.-E. Ebelin |
Implementation of pharmacometric approaches into clinical drug development? A prospective view |
| 16:05-16:25 |
L.B. Sheiner |
The future place of modeling in drug development |
| 16:25-16:45 |
C. Peck, F. Mentre, L. Aarons |
Discussion |
| |
|
|
|
| 16:45-17:00 |
Future of PAG(E) : Proposals: P. Girard |
| |
|
| 17:00-18:00 |
Poster and software session (see below) |
| |
| Tuesday June 14 |
| |
Oral session V |
|
chair: Carl Peck |
| 09:00-09:45 |
J. Wakefield |
Tutorial : Review of methods |
| 09:45-10:15 |
L. Aarons |
Software+ COST recommendations |
| 10:15-10:45 |
S. Lettis, E. Fuseau |
Simulation data : status report |
| 10:45-11:00 |
P. Girard |
Future of PAG(E) : Decision |
| 11:00-11:30 |
Coffee break |
| |
|
| 11:30-14:00 |
Poster and software session (see below) |
| |
|
| 14:00 |
End of the meeting |
Software demonstrations:
APIS (A. Iliadis)
MICROPHARM (S.Urien)
NONMEM PC (C.Pobel)
NONMEM VAX (V. Cosson)
NPEM (X. Barbaut)
NPML (Y. Merlé)
POPKAN (J. Wakefield)
P-PHARM (R. Gomeni)
Poster Presentations
1. M.O. Karlsson Stability of covariate models.
2. L. Claret, A. Iliadis Non-parametric density estimation applied to population studies.
3. O. Petricoul, A. Iliadis, L. Claret, C. Puozzo Information theory in drug development. Applications to a new antidepressant.
4. J. Bennett, J.C. Wakefield Covariate identification for population pharmacokinetic modelling.
5. S. Walker, J.C. Wakefield The population analysis of a dose ranging study.
6. E.M. Parker, M. Hutchison Pharmacokinetics of meropenem in pediatrics NONMEN analysis.
7. P. Burtin, E. Jacqz-Aigrin, P. Girard Population pharmacokinetics of midazolam in neonates.
8. D. de Alwis, L. Aarons, J. Palmer The population pharmacokinetics of ondansetron from phase I studies.
9. A.C. Falcao, M.M. Fernandez De Gatta, M.F. Delgado Iribarnegaray, D. Santos Buelga, M.J. Garcia, A. Dominguez-Gil, J.M. Lanao Caffeine pharmacokinetics in a pediatric population.
10. C. Laveille, M. Malbezin, D. Guez, R. Jochemsen Pharmacokinetics of S-12024 by a prospective population approach in phase II.
11. V. Cosson, J.-M. Scherrmann, E. Fuseau Population pharmacokinetics of oral sumatriptan.
12. S.F. Marshall, H.L. Elliott, P.A. Meredith A population approach to dose versus response relationship for simvastatin in hypertensive hypercholesterolaemic patients.
13. L.F. Lacey, L. Kler Effect of covariates on steady-state trough plasma bismuth concentrations from GR122311X in duodenal ulcer patients.
14. M. Tod, C. Pobel, O. Petitjean, N. Brion, J. Garcia-Mace A population pharmacokinetic study of alminoprofen penetration into synovial fluid.
15. M. Tod, J.M. Rocchisani Optimal sampling times determination by criteria incorporating knowledge of parameter distribution in the population.
16. N. Jonsson, J.R. Wade, M.O. Karlsson Comparison of practical sampling strategies for population pharmacokinetic studies.
17. L. Evans, L. Aarons Use of the EM algorithm in population pharmacokinetic analysis.
18. M.T. Mateu, J.J. Perez-Ruixo, V.G. Casabo, N.V. Jimenez Estimation of population pharmacokinetic parameters of tobramycin in intensive care unit patients using different programs.
19. D. Breilh, C. Pobel, L. Lagagnier, P. Maire, M.C. SauX Evaluation of bayesian estimators for adaptative control of vancomycin built with two methods of population modeling
20. B. Charpiat, N. Laurent, J.M Sab, V. Breant, C. Ducerf, S. Tigaud, D. Robert, R.W. Jelliffe Cyclosporine population pharmacokinetic parameters in the early post-operative hepatic transplantation phase: preliminary results.
21. M. Jerling, Y. Merle, F. Mentre, A. Mallet Population pharmacokinetics of nortriptyline at monotherapy and during concomitant treatment with drugs that inhibit CYP2D6 – an evaluation with the nonparametric maximum likelihood method.
